Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
26-06-26	GBX 1.900	0.00%	35,217
26-06-25	GBX 1.900	0.00%	104,107
26-06-24	GBX 1.900	0.00%	260,119
26-06-23	GBX 1.900	0.00%	244,919
26-06-22	GBX 1.900	0.00%	85,519

Delayed Quote London S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - London S.E. Other stock markets 11:35:12 2026-06-26 EDT			5-day change	1st Jan Change
1.900 ^GBX	0.00%		0.00%	-67.80%

05-12	Renalytix PLC And Carna Health Partner To Solve Kidney Disease Crisis	CI
04-22	EARNINGS AND TRADING: PensionBee sales jump 38%; Insig AI CEO invests	AN

Market Cap	10.97M 9.62M 8.87M 8.3M 15.57M 1.04B 15.89M 107M 41.25M 512M 41.21M 40.31M 1.77B	P/E 2024	-0.45x	P/E 2025	-1.34x
Enterprise Value	15.57M 13.66M 12.59M 11.78M 22.1M 1.47B 22.56M 151M 58.54M 726M 58.48M 57.2M 2.52B	EV / Sales 2024	11,059,330x	EV / Sales 2025	12,499,418x
Free-Float	73.31%	Yield 2024 *	-	Yield 2025	-

05-12	Renalytix PLC And Carna Health Partner To Solve Kidney Disease Crisis	CI
04-22	EARNINGS AND TRADING: PensionBee sales jump 38%; Insig AI CEO invests	AN
04-22	Renalytix Completes Laboratory Operations Transfer to New Facility in New York	MT
04-22	Renalytix plc Announces the Successful Completion of the Transfer of Laboratory Operations to a State of the Art Facility in New York	CI
03-31	Verici Dx plc Announces Resignation of James Mccullough as Non-Executive Director, Effective 31 March 2026	CI
03-26	EARNINGS AND TRADING: Tribal hikes dividend, profit more than doubles	AN
03-26	Renalytix Plc Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-11	Renalytix sinks as first half revenue ramp-up misses expectations	AN
02-11	AIM WINNERS & LOSERS: IG Design jumps on margin outlook	AN
02-11	Renalytix Plc Provides Earnings Guidance for the Year 2026	CI
01-13	Litigation Capital Management announces court win	AN
01-12	Renalytix Finalizes Chronic Kidney Disease Test Integration with Three US Healthcare Providers	MT
01-12	Renalytix plc Completes Three Additional Health Care Provider Clinical Integrations in United States	CI

23-04-03	BTIG Adjusts Price Target on Renalytix to $3.50 From $4, Maintains Buy Rating	MT
23-04-03	HC Wainwright Adjusts Price Target on Renalytix to $5 From $8, Maintains Buy Rating	MT
22-11-01	HC Wainwright Adjusts Renalytix's Price Target to $10 From $15, Keeps Buy Rating	MT
22-07-01	BTIG Adjusts Renalytix's Price Target to $5 From $15, Maintains Buy Rating	MT
22-07-01	Stifel Adjusts Renalytix's Price Target to $7 from $17, Keeps Buy Rating	MT

Renalytix Plc Stock

Stocks

RENX

GB00BYWL4Y04

Advanced Medical Equipment & Technology

Valuation: Renalytix Plc

Chart: Renalytix Plc

Latest news : Renalytix Plc

Analysts' recommendations: Renalytix Plc

Press Releases: Renalytix Plc

News in other languages: Renalytix Plc

Quotes and Performance

Course Extremes

Managers and Directors: Renalytix Plc

Latest insider transactions

Medical Diagnostic & Testing Equipment

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

04-13	Renalytix : Fincial document - (RENX Half Year Report 26.03.26)	PU
11-18	Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes	PR
25-09-15	Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease	PR
24-12-20	Renalytix : Result of AGM Form 8 K	PU
24-11-26	Renalytix : Proxy Card 2024 (for holders of ADSs)	PU

23-06-30	Aktien New York Schluss: Nasdaq 100 mit Rekordplus im ersten Halbjahr
23-06-30	Aktien New York: Deutliche Gewinne untermauern gute Wochen- und Halbjahresbilanz
23-06-30	Aktien New York Ausblick: Positiver Wochen- und Halbjahresabschluss in Aussicht
23-06-30	USA-Les valeurs à suivre à Wall Street (actualisé)
22-06-30	Point sur les fortes variations du jour : Metabolic Explorer se fait étrillé

Current month	+5.56%
1 month	+5.56%
3 months	-19.15%
6 months	-67.80%
Current year	-67.80%

1 week	1.8	2
1 month	1.6	2
Current year	1.6	6.5
1 year	1.6	15.5
3 years	1.6	150
5 years	1.6	1,190
10 years	1.6	1,220

Manager	Title	Age	Since
James McCullough CEO	Chief Executive Officer	58	2018-03-14
Joel Jung DFI	Director of Finance/CFO	68	2024-05-27
Howard Doran PSD	President	65	2024-04-29

Director	Title	Age	Since
Julian Baines CHM	Chairman	62	2024-11-04
James McCullough BRD	Director/Board Member	58	2018-03-14
Christopher Mills CHM	Chairman	74	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
02-12	James McCullough	Buy	Founder	250	0.0001%
02-12	Joel Jung	Buy	Chief Financial Officer	500	0.0001%
02-12	James McCullough	Buy	Founder	500	0.0001%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RENALYTIX PLC	0.00%	0.00%	-73.79%	-97.70%	10.97M
SARTORIUS AG	-2.69%	+5.16%	+2.71%	-27.20%	16.08B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	-5.09%	-7.73%	+19.73%	+39.52%	1.44B
ECKERT & ZIEGLER SE	-0.65%	-1.61%	-30.93%	+26.25%	1.09B
QUIDELORTHO CORPORATION	+2.00%	+0.88%	-51.95%	-83.55%	940M
CONTEC MEDICAL SYSTEMS CO.,LTD	-4.81%	-9.65%	-26.11%	-54.16%	608M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-4.26%	+1.87%	-38.83%	-56.04%	561M
VAREX IMAGING CORPORATION	0.00%	-2.28%	+20.49%	-54.56%	434M
REVENIO GROUP OYJ	-1.57%	0.00%	-54.56%	-60.75%	380M
CELLAVISION AB	-2.02%	-0.58%	-24.11%	-23.94%	334M
Average	-1.91%	-1.98%	-25.74%	-39.21%	2.19B
Weighted average by Cap.	-2.56%	+2.82%	-3.16%	-25.16%

	2024	2025
Net sales	2.29 2.01 1.85 1.73 3.25 215.93 3.32 22.24 8.6 106.72 8.6 8.41 370.04	3 2.63 2.42 2.27 4.26 283 4.34 29.14 11.28 139.86 11.26 11.02 484.99
Net income	-33.46M -29.33M -27.04M -25.31M -47.47M -3.16B -48.45M -325M -126M -1.56B -126M -123M -5.41B	-20.4M -17.89M -16.49M -15.44M -28.94M -1.92B -29.55M -198M -76.68M -951M -76.6M -74.93M -3.3B
Net Debt	3.86M 3.38M 3.12M 2.92M 5.47M 364M 5.58M 37.45M 14.49M 180M 14.48M 14.16M 623M	4.6M 4.03M 3.72M 3.48M 6.53M 434M 6.66M 44.68M 17.29M 214M 17.27M 16.9M 744M